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Abstract
Background: Chronic inflammatory diseases including inflammatory bowel disease (IBD; Crohn's disease and 
ulcerative colitis), psoriasis and rheumatoid arthritis (RA) afflict millions of people worldwide, but their pathogenesis is 
still not well understood.
It is also not well known if distinct changes in gene expression characterize these diseases and if these patterns can
discriminate between diseased and control patients and/or stratify the disease. The main focus of our work was the
identification of novel markers that overlap among the 3 diseases or discriminate them from each other.
Methods: Diseased (n = 13, n = 15 and n = 12 in IBD, psoriasis and RA respectively) and healthy patients (n = 18) were 
recruited based on strict inclusion and exclusion criteria; peripheral blood samples were collected by clinicians (30 ml) 
in Venous Blood Vacuum Collection Tubes containing EDTA and peripheral blood mononuclear cells were separated by 
Ficoll gradient centrifugation. RNA was extracted using Trizol reagent. Gene expression data was obtained using 
TaqMan Low Density Array (TLDA) containing 96 genes that were selected by an algorithm and the statistical analyses 
were performed in Prism by using non-parametric Mann-Whitney U test (P-values < 0.05).
Results: Here we show that using a panel of 96 disease associated genes and measuring mRNA expression levels in 
peripheral blood derived mononuclear cells; we could identify disease-specific gene panels that separate each disease 
from healthy controls. In addition, a panel of five genes such as ADM, AQP9, CXCL2, IL10 and NAMPT discriminates 
between all samples from patients with chronic inflammation and healthy controls. We also found genes that stratify 
the diseases and separate different subtypes or different states of prognosis in each condition.
Conclusions: These findings and the identification of five universal markers of chronic inflammation suggest that 
these diseases have a common background in pathomechanism, but still can be separated by peripheral blood gene 
expression. Importantly, the identified genes can be associated with overlapping biological processes including 
changed inflammatory response. Gene panels based on such markers can play a major role in the development of 
personalized medicine, in monitoring disease progression and can lead to the identification of new potential drug 
targets in chronic inflammation.
Background
Chronic inflammatory diseases such as inflammatory
bowel disease (IBD; including Crohn's disease - CD and
ulcerative colitis - UC), psoriasis and rheumatoid arthritis
(RA) exist as a substantial burden in social and economic
terms worldwide. Despite the importance of these dis-
eases, it is still not clear if characteristic gene expression
signatures can discriminate this group of diseases from
healthy controls, the various diseases from each other or
whether it is possible to stratify the diseases based on
gene expression changes.
These chronic conditions have common features such
as the autoimmune origin, the frequent co-morbidity and
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a few genes such as IL10, IL23R, SLC22A4 and SLC22A5
that have been identified as contributors to their genetic
background [Table 1]. However their prevalence and the
tissues affected are clearly different.
RA is a systemic autoimmune disorder, with a preva-
lence between 0.5-1.0% [1], that causes inflammation and
tissue damage in joints and tendon sheaths. Psoriasis
which is a chronic disorder of the skin and joints where
the psoriatic plaques are areas of inflammation and
excessive skin production, affects approximately 2% of
the population only in the USA [2]. 1-2% of Western pop-
ulations suffer from IBD [3] in which the common fea-
tures are the inflammation of the intestines and the
autoimmune origin.
Global and selective gene expression analyses have
already been performed in order to gather hints on the
mechanisms of these medical conditions by using human
biopsy samples such as colon tissue in IBD [4]; skin tissue
in psoriasis [5] and synovial tissue biopsy in RA [6]. How-
ever peripheral blood is a more accessible source of cells
and may be easier to use for screening processes. Further-
more as circulating peripheral blood mononuclear cells
(PBMCs) are key cells of inflammation, it may also reflect
disease mechanisms.
In addition studies of gene expression profiling of
PMBCs may provide a more cost effective and less inva-
sive alternative to biopsy or invasive measurements [7].
Examples of the clinical implications of this approach
include the analysis of human breast cancer progression
[8] and PBMC profiles in RA, systemic lupus erythemato-
sus, type I diabetes and multiple sclerosis [9].
It appears therefore that gene expression profiling from
PBMCs is a validated tool for discovery and also may be
used to explore the pathogenetic background of these
medical conditions [10-12]. However comparative studies
on the existence of distinct and overlapping gene expres-
sion patterns are lacking. We sought to fill this gap by car-
rying out a comparative analysis of peripheral gene
expression patterns of a panel containing 96 genes in var-
ious chronic inflammatory diseases and healthy controls.
Methods
Patient recruitment
The Research Ethics Committee of University of Debre-
cen Medical and Health Science Center approved the
Table 1: Known SNP - disease associations
Gene IBD Psoriasis Rheumatoid arthritis
ADAM33 NA rs512625 PMID: 18560587 NA
IL10 rs3024505 PMID: 18836448 NA rs1800896 PMID: 18615156
IL13 NA rs1800925 PMID: 19554022 NA
IL23R rs2201841 PMID: 18338763 rs11209026 PMID: 18369459 NA
IL4 rs2243250 PMID: 18064451 NA NA
IL8 NA NA PMID: 18799095
PADI4 NA NA rs2240340 PMID: 12833157
PTGS2 rs20432 PMID: 16273614 NA rs5275 PMID: 18381795
PTPN22 NA rs1217414 PMID: 18341666 rs2476601 PMID: 18466513
SLC22A4 rs3792876 PMID: 17476680 rs11568506 PMID: 18614543 rs3792876 PMID: 15107849
SLC22A5 rs3792876 PMID: 17476680 rs2631367 PMID: 16255050 rs2631367 PMID: 15107849
Known associations between single nucleotide polymorphisms and chronic inflammatory diseases are shown in the table with SNP ID and 
PMID number referring to the publication that documents the association. NA means there is no documented association on SNP level. Bold 
cells mean we could detect the association in our study between that specific disease and healthy controls.Mesko et al. BMC Medical Genomics 2010, 3:15
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clinical protocol and the study that were in compliance
with the Helsinki Declaration. Signed informed consent
was obtained from all healthy and diseased individuals
who provided blood sample. Inclusion and exclusion cri-
teria were developed using the best evidence currently
available. Online supplement is provided for additional
information about inclusion and exclusion criteria [Addi-
tional File 1: Figure S2].
The study included 13 patients with IBD; 15 with psori-
asis and 12 with RA, all of whom had active disease and
were medication-free at the time of blood draw [Table 2].
Blood was also obtained from a group of healthy control
individuals (18 patients) that did not show significant dif-
ferences compared to the diseased groups regarding age.
After the subjects fasted overnight for 12 hours, all of the
blood samples were obtained locally between 8:00 AM
and 9:00 AM; and were processed within one hour after
sample collection.
Peripheral blood mononuclear cell collection and RNA 
processing
Venous peripheral blood samples were collected by clini-
cians (30 ml) in Venous Blood Vacuum Collection Tubes
containing EDTA (BD Vacutainer K2E). PBMCs were
separated by Ficoll gradient centrifugation.
Total RNA was extracted from PBMCs using Trizol
reagent (Invitrogen), according to the manufacturer's
protocol. RNA quality and quantity were checked on
NanoDrop and Agilent Bioanalyser 2100 (Agilent Tech-
nologies).
TaqMan mRNA analysis by RT-QPCR
Gene expression data was obtained using TaqMan Low
Density Array (TLDA) (Applied Biosystems) which is a
384-well micro fluidic card that enables to perform 384
simultaneous real-time PCR runs and which has been
used for gene expression profiling in several studies
[13,14]. This low- to medium- throughput micro fluidic
card allows for 2 samples to be run in parallel against 96
TaqMan®  Gene Expression Assay targets that are pre-
loaded into each of the wells on the card. cDNA was gen-
erated with High Capacity cDNA Reverse Transcription
Kit according to manufacturer's protocol. 2 micrograms
of RNA were used per sample in the RT-PCR runs. 400 ng
(4 μl) cDNA was used in each sample. 196 μl nuclease-
free water and 200 μl 2× TaqMan Universal PCR Master
Mix (Applied Biosystems) were added for the Real-Time
Quantitative PCR measurements. This mixture was then
equally divided over four sample-loading ports of the
TLDA, each connected to one set of the 96 genes of inter-
est. The arrays were centrifuged once (1', 1300 RPM on
room temperature) to equally distribute the sample over
the wells. Subsequently, the card was sealed to prevent an
exchange between wells. RT-QPCR amplification was
performed using an Applied Biosystems Prism 7900HT
sequence detection system with the following thermal
Table 2: Patient parameters
Disease Status Control IBD Psoriasis Rheumatoid 
arthritis
n 1 81 31 5 1 2
Sex (male/female) 8/10 4/9 5/10 2/10
Age (years) 40.07 ± 21.3 27.92 ± 8.49 30.53 ± 9.3 45.83 ± 18.24
Clinical subtype NA CD/UC 8/4 Arthritis positive/
negative 4/11
Bone erosion 
positive/negative 
4/8
CDAI UCDAI PASI DAS28
Clinical severity NA 270.4 ± 67.18 8 ± 1.2 27.47 ± 9.62 6.12 ± 1.05
124-365 6-9 15-48 4.07-7.56
Definition of abbreviations: IBD = Inflammatory bowel disease, CD = Crohn's Disease, CDAI = Crohn's Disease Activity Index, UC = Ulcerative 
colitis, UC DAI = Ulcerative Colitis Disease Activity Index, PASI = Psoriasis Area Severity Index, DAS28 = Disease Activity Score 28, NA = non 
available. Data are presented as mean ± SD; also range in Clinical Severity.Mesko et al. BMC Medical Genomics 2010, 3:15
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cycler conditions: 2 min at 50°C and 10 min at 94.5°C, fol-
lowed by 40 cycles of 30 s at 97°C and 1 min at 59.7°C.
Gene List Selection Process
A database containing 400 genes which are associated
with the 3 chronic inflammatory diseases and inflamma-
tion was constructed by using the data derived from the
Human Genome Navigator that lists all the genes related
to a specific disease and the evidence the relation is based
on; the current medical literature and international data-
bases (e.g. OMIM, Entrez Gene). Genes were also
selected from genome-wide association studies as well as
microarray analyses focusing on skin biopsy in psoriasis,
colon biopsy in IBD and synovial fluid in RA. (Figure 1)
In the second step, genes were put in order by using a
score list that was based on the number of publications
mentioning the disease-gene association, relation to
other diseases and expected expression in PBMC accord-
ing to previous studies and our pilot experiment in which
we analyzed selected genes in PBMC samples through
individual RT-QPCR assays. This selection process
resulted in 150 genes.
In the third step, genes that did not show expression
(missing signal in QPCR measurements) in the pilot
study were removed, leading to a final list of 96 genes
Additional File 1: Figure S1.
Statistical Analyses
Relative gene expression levels of each gene were calcu-
lated by comparative Ct method and results were normal-
ized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) expression for each sample. Statistical analyses
of the normalized gene expression data were performed
in Prism (GraphPad). Due to the fact that our data did not
follow normal distributions, the gene expression in
groups with different numbers of samples was compared
separately using the non-parametric Mann-Whitney U
test. P-values < 0.05 were considered to be statistically
significant. This method that does not include correction
for multiple comparisons is widely used in the analysis of
TLDA data [15,13] and is explained in details in [16].
Gene interactions were analyzed by using the Direct
Interactions and Biological Processes functions of Gene-
Spring GX (Agilent Technologies).
Principal component analysis (PCA), a standard, non-
parametric tool that reduces a complex data set to a lower
dimension, was used in order to reveal the internal struc-
ture of the data sets and to project the differences
between diseased and healthy groups based on each set of
significantly changing genes.
Results
Identification of gene panels discriminating chronic 
inflammatory disease patients from healthy controls
A panel of 96 genes has been selected by the algorithm
depicted on Figure 1. Patients were recruited and PBMC
gene expression was determined as described in Materi-
als and Methods. When we compared the gene expres-
sion results we have found 53 genes that show significant
differences between diseased and healthy samples. First,
we looked at the gene panels that differentiate each dis-
ease from the set of control samples. Altogether 25 genes
show significant differences between IBD; 16 genes
between psoriasis; 33 genes between RA and controls
(Figure 2a-c). Principal component analysis of these gene
sets also separates the different groups of samples. In
order to get hints of the complex transcriptional basis of
inflammatory diseases and to find potential targets that
might play a role in the pathogenesis of the conditions,
the interaction among multiple genes needs to be
revealed. Gene interaction analyses highlighted IFNG,
IL4, IL10, MMP9 and TIMP1 in IBD; IL10, IL13 and
PTGS2 in psoriasis; IL8, IL10 and PTGS2 in RA. These
genes had the most direct interactions that might reveal
their key role in the pathogenetic background of the dis-
eases. Gene interaction analysis on each set of genes is
provided in the supplement material Additional File 1:
Figure S3-5.
Gene sets showing overlapping or differential expression
In order to analyze the gene expression patterns of these
conditions, first we created a Venn diagram highlighting
those genes that differentiate between a disease and the
set of control samples (Figure 3a).
Figure 1 Flowchart of gene selection process. A flow chart of the 
gene selection process shows the steps through which we chose the 
final 96 genes out of the database containing 400 genes.Mesko et al. BMC Medical Genomics 2010, 3:15
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Performing Gene Interaction Analysis resulted in the
identification of a network that highlights the genes with
the most interactions such as CCL5, IFNG, IL4, IL8, IL10,
IL13, MMP9, PTGS2 and TIMP1 (Figure 3b) clearly
showing that not only individual genes but entire net-
works are impacted and hence can be identified.
Although there are genes that showed disease specific
signatures, all of these genes showing significant differ-
ences between diseased and healthy samples form a net-
work which might represent the common background of
the pathogenesis of this type of inflammation.
As the next step in our analysis all the significantly
changing genes were assigned to functional categories
that were created based on EASE, the Expression Analy-
sis Systematic Explorer that provides statistical methods
for discovering biological themes within gene lists [17].
Genes were grouped into inflammatory response; cell
growth and maintenance; proteolysis; metabolism and
unclassified (including genes in unique categories or
genes without categories) categories with 21, 11, 7, 9 and
7 genes respectively. In order to illustrate the similarities
in the pathogenetic background of these diseases, the
functional categories, the number of genes and the dis-
ease gene panels are visualized. It shows that there are
similar number of genes in the same functional categories
in each of the diseases, though the number of unique
genes (11 in IBD, 6 in psoriasis and 21 in RA) separating
only a disease from the control group is also high (Figure
4).
Diseases subtype stratification by differentially expressed 
genes
We also sought to identify potential markers that differ-
entiate between distinct subtypes or states of prognosis in
each of the three diseases to stratify the disease based on
gene expression patterns (Figure 5). Analyses of individ-
ual genes are provided in the supplement material Addi-
tional File 1: Figure S7-9.
Figure 2 Fold changes of genes differentiating between diseased and control samples. Fold change values of genes, showing statistically sig-
nificant (Mann-Whitney U test) differential expression between diseased and control patients, were generated from RT-QPCR measurements and rep-
resent the difference of the means of the diseased and control groups. Principal component analysis was performed and separates the two groups of 
samples. 2a represents the IBD, 2b the psoriasis and 2c the RA gene panel.Mesko et al. BMC Medical Genomics 2010, 3:15
http://www.biomedcentral.com/1755-8794/3/15
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Regarding IBD, ADAM10, CUGBP1, CUGBP2, DUSP1,
ETS2, FOS, IL6, IL18 and PGRMC1 show significantly
higher expression levels in patients with CD compared to
patients with UC (Figure 5a).
In psoriasis, CCL4, GZMK and KLRF1 show signifi-
cantly higher, while ADM, ANXA3, IL4, MMP9 and
OLR1 show significantly lower expression levels in
patients with arthritis negative psoriasis compared to
patients with symptoms of arthritis (Figure 5b).
HBB and PADI4 show lower; GZMK shows higher
expression in RA patients with bone erosions confirmed
with Magnetic Resonance Imaging compared to those
without such symptoms (Figure 5c).
Peripheral blood derived universal markers of chronic 
inflammation
Importantly, we have identified five genes, ADM, AQP9,
CXCL2, IL10 and NAMPT that show significant differ-
ences in expression levels between all the three condi-
tions and control samples (Figure 6). These genes might
be considered universal markers of chronic inflammation
in PBMCs. Regarding pathway analysis that features the
biological processes the genes are associated with; IL10
has the highest number of related biological processes
(over 20) including lymphocyte, T and B cell prolifera-
tion, interleukin production and macrophage activation.
ADM is related to 10 processes such as activation of
MAPK-activity and interleukin-6 production; while
AQP9, CXCL2 and NAMPT are only associated with a
single process, urea transport, interleukin-18 production
and neutrophil apoptosis, respectively (Figure 7).
We also determined the number of diseased patients
with gene expression levels above the range of the mean +
SD or 2 SD of control samples. Additional File 1: Figure
S6.
Discussion
It is of critical importance to identify new biomarkers and
hints of mechanisms of disease states and disease pro-
gression in illnesses affecting large populations such as
chronic inflammatory diseases in order to personalize
treatment and accurately monitor disease progression.
Methods based on genomic approaches and amongst
them global gene expression profiles play an increasing
role in such efforts.
The pathomechanism of these chronic inflammatory
diseases has been examined at different levels including
cell cultures, animal models and clinical samples. Impor-
tantly, as the molecular signature of disease across tissues
is overall more prominent than the signature of tissue
expression across diseases [18], there is good reason to
believe one can detect disease-specific gene expression
signatures in PBMC samples which are easy-to-access.
There have been studies analyzing the gene expression
patterns of these diseases in PBMC samples which led to
the identification of genes, which we also found to be sig-
nificantly different between disease and control patients.
Examples include PTGS2 in psoriasis [10]; PTPN22 in
RA [19] and GZMK in IBD [12]. Other groups compared
Figure 3 Genes separating chronic inflammatory diseases from controls. (a) Venn diagram shows all of those genes that show significant differ-
ences between each disease group and control samples. Each set contains genes that separate control samples only from the particular disease or 
diseases. Underlined genes were down-regulated compared to healthy controls. (b) Gene interaction analysis in GeneSpring GX in Direct Interactions 
mode highlights 28 genes that have direct interactions with each other while 25 genes have no direct interactions. Genes with the highest number 
of interactions are shown in extended size. Cyclooxygenase 2 enzyme is located in the middle of this pathway network. The genes that showed sig-
nificant differences between one of the diseased groups and healthy controls have color codes in which blue represents RA, green represents IBD and 
red codes for psoriasis-related genes.Mesko et al. BMC Medical Genomics 2010, 3:15
http://www.biomedcentral.com/1755-8794/3/15
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Figure 4 Functional categorization of significantly changing genes. We found 53 genes that show significantly differences between chronic in-
flammatory diseases and control samples. These genes were grouped into functional categories made by EASE. Genes were grouped in the category 
that had the highest relevance according to the EASE software. Colors represent disease groups. The size of the diagrams correlates with the number 
of genes in each set. Overlapping sets of genes are shown as overlapping diagrams.
Figure 5 Correlation between gene expression levels and clinical parameters. Normalized mRNA levels of genes showing significant differences 
between patients with (a) Crohn's disease and Ulcerative colitis; (b) psoriasis patients with and without arthritis; (c) RA patients with and without MR-
confirmed bone erosion were generated from RT-QPCR measurements and represent the means of the expression levels of the diseased and control 
groups.Mesko et al. BMC Medical Genomics 2010, 3:15
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different chronic disorders to each others such as juvenile
arthritis and spondyloarthropathy [20] or psoriatic
arthritis, RA and spondyloarthropathy [21], but such an
extended number of genes have not yet been found in
peripheral blood. Importantly the gene expression pro-
files of RA, IBD and psoriasis have not been compared
previously. We tried to fill this gap with our study and
identify markers of chronic inflammation that overlap
among the 3 conditions and also ones that discriminate
them from each other.
It should be noted though gene expression analyses of
these diseases provide little insight into the pathomecha-
nisms of the disease simply because it is impossible to
sort out what is cause and what is consequence. However
it can still provide hints or clues about the potential path-
ways affected. Therefore such datasets, although indi-
rectly, can form the basis of more mechanistic studies.
This is why we have carried out and presented the gene
interaction analyses of the genes identified and linked to
the different diseases. Significantly the existence of over-
lapping gene sets suggests that there are common path-
ways impacted among the studied diseases. A common
characteristic of all diseases is an altered inflammatory
response.
In addition, genetic association studies have already
identified SNPs linked to these diseases. A comparison of
our dataset to these can provide further support to those
findings [Table 1].
Several of the now identified differentially expressed
genes have been linked to the studied diseases although
either at a different level or different model. Regarding
the IBD gene panel, OLR1/LOX1 [22] and CCR1 [23]
both have immune response function and are expressed
in human intestinal cells. The homophilic ligation of
Figure 6 Peripheral blood derived universal markers of chronic inflammation. Normalized mRNA levels of genes (with SD) showing significant 
differences between all the samples of chronic inflammatory diseases and healthy controls were generated from RT-QPCR measurements.Mesko et al. BMC Medical Genomics 2010, 3:15
http://www.biomedcentral.com/1755-8794/3/15
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CEACAM1, which is a cell-surface molecule, on T cells
leads to the inhibition of a range of T-cell functions there-
fore it might be a new potential therapeutic target in the
treatment of IBD [24]. MMP9, a gelatinase, that showed a
7-fold up-regulation in diseased samples in our study is
an important mediator of tissue injury in colitis and is up-
regulated in sputum samples of CD patients [25]. Garg et
al. suggested that developing strategies to block MMP-9
activity in the gut might be of benefit to IBD [26]. TIMP1
is a natural inhibitor of matrix metalloproteinases
(MMPs) and might be considered a potential drug target.
The DNA methylation of IFNG that regulates immune
response was analyzed within the mucosal compartment
in both normal and IBD populations [27]. PTGS2/COX2
is related to IBD expression level in colon biopsy [28].
ABCA1, BASP1, GZMK, HBB, SEC14L1, THEM2 and
TNFAIP6 have never been associated with IBD; therefore
further analyses should be carried out.
In the psoriasis panel, CCR1 that plays a role in inflam-
matory response is associated with psoriasis via the anal-
ysis of skin lesion samples [29]. Koczan et al. identified
pairs of genes such as PTGS2/COX2 and NR1D2 which
allowed an accuracy of disease stage prediction of 86%,
based on gene expression patterns [10]. ADORA2B,
IFRD1, ITGA2B, MAP4K1, PADI4, PDE4A, SEC14L1
and TREM1 have no documented association with psori-
asis yet. Therefore these are candidates for further SNP/
genetic association or mechanistic studies.
Regarding the significantly changing genes in RA sam-
ples, IL8 is related to RA based on expression [30]. Van
Der Voort et al. demonstrated that the expression of
ADAM10 is strongly enhanced in RA synovia [31]. CCL4
was expressed in PBMC [30] and CCL5 showed high
serum levels [32]. Kehlen et al. found up-regulation of
TNFAIP6 in fibroblast-like synoviocytes of patients with
RA [33]. HMGB1 [34] and PLCB1 [35] only showed dif-
Figure 7 Pathway analysis of universal markers of chronic inflammation. Pathway analysis was carried out with GeneSpring GX Biological Pro-
cesses mode that revealed all the biological processes the genes are related to. Circles represent the 5 genes; deltoids represent biological processes.Mesko et al. BMC Medical Genomics 2010, 3:15
http://www.biomedcentral.com/1755-8794/3/15
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ference in protein level in RA patients. PTGS2/COX2
mRNA levels in PBMC samples from RA patients were
within the normal range or below normal [36]. ADAM12,
ADAM33, ADORA2B, AKT3, ANXA3, CDKN1C,
CTSL1, CUGBP1, CUGBP2, CYP51A1, FGL2, HBB,
HSP90AA1, KLRF1, NR1D2, SLC33A1 and THEM2 have
no evidence of association with RA and should further be
studied.
Gene expression profiling may allow early diagnosis,
aid in identifying prognosis or subtypes. We found genes
that differentiate between CD and UC in IBD of which
some have already been associated with the disease but at
a different level or in a different tissue. Alexander et al.
reported that the expression level of FOS was two- to
threefold higher in involved than in uninvolved areas of
the colons of two UC patients [37]. van der Pouw Kraan
at el. found that ETS2 may be an important transcription
factor driving inflammation in acute as well as chronic
inflammatory diseases such as IBD [38]. As oppose to
UC, IL-18 may serve as indicators of acute phase reactiv-
ity in CD, according to Haas et al. [39], that correlates
with our findings. Mitsuyama et al. suggested that IL-6
trans-signaling may play role in the development of IBD
and imply the possibility of a selective therapeutic strat-
egy to target this signaling [40].
A gene panel containing 8 genes shows significant dif-
ferences between patients with and without arthritis in
psoriasis. Hitchon et al. described that MMPs, especially
MMP2 and MMP9, have been implicated in several fea-
tures of inflammatory arthritis including angiogenesis
and bone erosions [41]. Partsch et al. measured the pro-
tein level of IL4 in synovial fluid of patients with psoriatic
arthritis (PsA) [42].
Another gene set including HBB, GZMK and PADI4
separates different states of prognosis in RA regarding
MR-confirmed bone erosion. In RA, PADI4 is a target of
autoantibodies; and its increased expression in synovia of
RA patients [43], also its relation to the disease at SNP
level have already been confirmed [44]. Osteoclasts are
shown to be mainly involved in the bone-destruction of
RA which may indicate further studies regarding the role
of PADI4 in bone erosion.
We consider a key aspect of our work is the identifica-
tion of five genes including ADM, AQP9, CXCL2, IL10
and NAMPT that differentiate between samples from
patients with chronic inflammation and healthy controls.
ADM that plays role in response to wounding is found to
be distributed on the surface of the human colonic
mucosa [45] and the plasma level of ADM in RA patients
was significantly higher compared to healthy controls in
synovial tissue [46]. CXCL2 that has function in immune
response is over-expressed in osteoarthritis fibroblasts
rather than rheumatoid fibroblasts [47], up-regulated in
psoriatic epidermis [48], and also in epithelial tissue [49].
IL10 is expressed in PBMCs of psoriasis [50], RA [51] and
IBD patients [52]. The expression of NAMPT which is a
pre-B cell-enhancing factor is increased in colonic biopsy
specimens of IBD patients compared to healthy controls
[53], it is also up-regulated in plasma and synovial fluid of
RA patients [54]; and in PBMC of psoriasis in the dis-
eased stage [10]. AQP9 that has an activity in immune
r e s p o n s e  h a s  n e v e r  b e e n  a s s o c i a t e d  w i t h  a n y  o f  t h e s e
medical conditions.
These genes might serve as universal markers of
chronic inflammation. As expected, IL10 seems to be the
key gene in this network regarding biological processes
(Figure 3b). As the number of biological processes related
to ADM is relatively high and it has no direct interactions
with the genes we examined, there might be other poten-
tial markers that play role in the pathomechanism of the
conditions we analyzed that also have similar pathways or
targets as ADM. Chronic inflammatory and autoimmune
diseases share a number of phenotypic and genetic char-
acteristics suggesting common etiological pathways or
pathomechanisms. Becker et al. used meta-analyses of
whole-genome scans and found non-random clustering
of disease susceptibility loci for autoimmune diseases
[55]. Our results may suggest that all of the chronic
inflammatory conditions we analyzed share similar
pathogenetic background as reflected by peripheral gene
expression.
Personalized medicine is becoming an integral part of
healthcare and the key challenge is to establish a strategic
focus on biomarker-based clinical tests. Non-invasive or
minimally invasive diagnostic tests present less danger to
a patient than invasive tests such as biopsies; and can help
clinicians by providing them with valuable information in
decision-making. A biomarker assay based on the gene
panels described above might save time by reducing a list
of preliminary disease impressions to a definitive diagno-
sis. The evaluation of these results and the identification
of genes with altered expression or marker genes could
also be potential targets for novel and more effective
therapies and may lead to important insights into the
pathogenesis of chronic inflammatory diseases. It might
also have benefits to look at the identified gene panels in
terms of SNPs in order to identify potential genetic
changes associated with these medical conditions. Such
novel and known biomarkers or a panel of such markers
can play a major role in the development of personalized
medicine.
Conclusion
Our results suggest that IBD, psoriasis and rheumatoid
arthritis have common pathogenetic background and
gene expression profiling from peripheral blood might
reveal novel targets and pathways affected by these dis-
eases.Mesko et al. BMC Medical Genomics 2010, 3:15
http://www.biomedcentral.com/1755-8794/3/15
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ABCA1: ATP-binding cassette, sub-family A, member 1; ADAM10: ADAM metal-
lopeptidase domain 10; ADAM12: ADAM metallopeptidase domain 12;
ADAM33: ADAM metallopeptidase domain 33; ADM: Adrenomedullin;
ADORA2B: adenosine A2b receptor; AKT3: v-akt murine thymoma viral onco-
gene homolog 3; ANXA3: annexin A3; AQP9: Aquaporin 9; BASP1: brain abun-
dant, membrane attached signal protein 1; CCL4: chemokine (C-C motif)
ligand 4; CCL5: chemokine (C-C motif) ligand 5; CCR1: chemokine (C-C motif)
receptor 1; CDKN1C: cyclin-dependent kinase inhibitor 1C; CEACAM1: carcino-
embryonic antigen-related cell adhesion molecule 1; CTSL1: cathepsin L1;
CUGBP1: CUG triplet repeat, RNA binding protein 1; CUGBP2: CUG triplet
repeat, RNA binding protein 2; CXCL2: chemokine (C-X-C motif) ligand 2;
CYP1B1: cytochrome P450, family 1, subfamily B, polypeptide 1; CYP51A1: cyto-
chrome P450, family 51, subfamily A, polypeptide 1; FGL2: fibrinogen-like 2; GK:
glycerol kinase; GZMK: granzyme K; HBB: hemoglobin, beta; HSP90AA1: heat
shock protein 90 kDa alpha (cytosolic), class A member 1; IBD: Inflammatory
bowel disease; IFNG: interferon gamma; IFRD1: interferon-related developmen-
tal regulator 1; IL10: Interleukin 10; IL13: Interleukin 13; IL23R: Interleukin 23
receptor; IL4: Interleukin 4; IL8: Interleukin 8; ITGA2B: integrin, alpha 2b; KLRF1:
killer cell lectin-like receptor subfamily F, member 1; MAP4K1: mitogen-acti-
vated protein kinase 1; MMP9: matrix metallopeptidase 9; NAMPT: nicotin-
amide phosphoribosyltransferase; NR1D2: nuclear receptor subfamily 1, group
D, member 2; OLR1: oxidized low density lipoprotein receptor 1; PADI4: pepti-
dyl arginine deiminase, type IV; PBMC: Peripheral Blood Mononuclear Cells;
PDE4A: cAMP-specific phosphodiesterase 4D; PLCB1: phospholipase C, beta 1
(phosphoinositide-specific); PTGS2: prostaglandin-endoperoxide synthase 2
(prostaglandin G/H synthase and cyclooxygenase); PTPN22: protein tyrosine
phosphatase, non-receptor type 22 (lymphoid); QPCR: Quantitative poly-
merase chain reaction; RA: Rheumatoid arthritis; SEC14L1: SEC14-like 1 (S. cere-
visiae); SLC22A4: solute carrier family 22 member 4; SLC22A5: solute carrier
family 22 member 5; SLC33A1: solute carrier family 33 member 1; THEM2: acyl-
CoA thioesterase 13; TIMP1: TIMP metallopeptidase inhibitor 1; TLDA: Taqman
Low Density Array; TNFAIP6: tumor necrosis factor, alpha-induced protein 6;
TREM1: triggering receptor expressed on myeloid cells 1
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